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Abstract
Previous studies have identified specific Burkholderia cepacia complex strains that are common to multiple persons with cystic fibrosis
(CF). Such so-called epidemic strains have an apparent enhanced capacity for inter-patient spread and reside primarily in Burkholderia
cenocepacia (formerly B. cepacia complex genomovar III). We sought to identify strains from B. cepacia complex species other than
B. cenocepacia that are similarly shared by multiple CF patients. We performed genotype analysis of 360 recent sputum culture isolates
from 360 persons residing in 29 cities by using repetitive extragenic palendromic polymerase chain reaction (rep-PCR) and pulsed field gel
electrophoresis. The results indicate that sharing of a common Burkholderia multivorans strain occurs relatively infrequently; however,
several small clusters of patients infected with the same strain were identified. A cluster of seven patients infected with the same B. cepacia
(genomovar I) strain was found. We also identified a large group of 28 patients receiving care in the same treatment center and infected
with the same Burkholderia dolosa strain. These observations suggest that B. cepacia complex strains in species other than B. cenocepacia
may be spread among CF patients.
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1. Introduction
Bacteria belonging to the Burkholderia cepacia complex
are important pathogens in persons with cystic ¢brosis
(CF). Respiratory tract infection may persist for months
or years or be associated with life-threatening acute illness
[1]. Numerous studies have provided compelling evidence
for transmission of ‘B. cepacia’ among CF patients. This
observation, as well as the ¢nding that most strains are
inherently resistant to broad-spectrum antibiotics, has
made prevention of infection a cornerstone of CF patient
management [2]. Stringent infection control policies that
segregate infected patients have decreased but not com-
pletely eliminated new infection. A better understanding
of the epidemiology and ecology of these species is a pre-
requisite to optimizing infection control policies and is
essential in e¡orts to elucidate the pathogenesis of human
infection.
Recent taxonomic work has de¢ned several phenotypi-
cally similar species (or genomovars) among bacteria pre-
viously identi¢ed merely as ‘B. cepacia’. The B. cepacia
complex is currently comprised of nine species, B. cepacia,
B. multivorans, B. cenocepacia, B. stabilis, B. vietnamiensis,
B. dolosa, B. ambifaria, B. anthina, and B. pyrrocinia (rep-
resenting genomovars I^IX, respectively) [3^6]. Among
these, B. multivorans and B. cenocepacia account for the
great majority of infection in CF [7^9].
Studies employing bacterial genotyping have identi¢ed
distinct B. cepacia complex strains that are shared by mul-
tiple CF patients. Most of the ‘epidemic’ strains described
to date are B. cenocepacia. Evidence of inter-patient
spread of strains belonging to other B. cepacia complex
species is more limited. In this study we examined a large
collection of B. cepacia complex isolates recently recovered
from US CF patients. Bacterial genotyping analysis was
0378-1097 / 03 / $22.00 7 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
doi :10.1016/S0378-1097(03)00724-9
* Corresponding author. Tel. : +1 (734) 615 5909;
Fax: +1 (734) 764 4279.
E-mail address: jlipuma@umich.edu (J.J. LiPuma).
FEMSLE 11242 30-10-03
FEMS Microbiology Letters 228 (2003) 57^62
www.fems-microbiology.org
undertaken to identify strains common to multiple pa-
tients.
2. Materials and methods
2.1. Bacterial strains and study design
Bacterial isolates were recovered from sputum culture
obtained between 1997 and 2003 during the course of rou-
tine health care of persons with CF attending treatment
centers in the USA. Isolates were con¢rmed as B. cepacia
complex and assigned to one of the nine species within this
group by using species-speci¢c 16S rDNA and recA-based
polymerase chain reaction (PCR) assays previously de-
scribed [10,11]. Only B. cepacia complex isolates belonging
to species other than B. cenocepacia were included in the
study. Study isolates were further limited to include only
those from treatment centers wherein at least six patients
were infected with the same B. cepacia complex species. In
cases where more than one isolate was available from a
given patient, only the ¢rst obtained was included in the
study. Strains that were shared by two or more non-sibling
patients attending the same treatment center were identi-
¢ed by genotyping analysis.
2.2. Genotyping analyses
Genotyping was performed using rep-PCR with a BOX
A1R primer (BOX-PCR) as previously described [12]. A
subset of isolates (as detailed in Section 3) was further
assessed by macrorestriction digestion of chromosomal
DNA and pulsed ¢eld gel electrophoresis (PFGE), also
as described previously [12]. For both analyses, densito-
metric analysis, normalization and interpolation of the
resulting patterns was performed using Quantity One 4.1
and Molecular Analyst Fingerprinting Plus software (Bio-
Rad). Similarity matrices were calculated using Pearson’s
product moment correlation coe⁄cient. Cluster analyses
of similarity matrices were performed by the unweighted
pair group method with arithmetic averages (UPGMA).
For BOX-PCR, a similarity coe⁄cient cuto¡ of 85% was
used to de¢ne isolates of the same strain. PFGE patterns
were analyzed according to published interpretive criteria
[13].
3. Results
From a database of 1356 CF patients infected with
B. cepacia complex and receiving care in 172 US cities,
360 isolates from 360 patients in 29 treatment centers
were analyzed based on the study inclusion criteria.
Groups of six or more patients attending the same center
and infected with B. multivorans, B. cepacia, or B. dolosa
were identi¢ed. We found no treatment centers in which at
least six non-sibling patients were infected with B. stabilis,
B. vietnamiensis, B. ambifaria, B. anthina or B. pyrrocinia.
3.1. B. multivorans clusters
There were 26 treatment centers wherein at least six
non-sibling patients were infected with B. multivorans. A
total of 319 isolates from as many patients were geno-
typed. In 14 of the 26 centers we identi¢ed at least two
non-sibling patients infected with the same strain (Table
1). Although pairs of patients harboring the same strain
were most common, we also identi¢ed several sets of three
and four patients with a shared strain. In center E, the
same strain infected six of 17 B. multivorans-infected pa-
tients. These isolates clustered by BOX-PCR with a sim-
ilarity coe⁄cient of 94% (Fig. 1A); this strain has been
designated strain OHBM. In center N, ¢ve of eight
B. multivorans-infected patients shared a common strain,
with isolates clustering by BOX-PCR with a similarity
coe⁄cient of 95% (Fig. 1A); this strain was designated
strain TUL2. All isolates from both clusters were further
analyzed by PFGE, which showed that isolates within
each group di¡ered by no more than two bands (data
not shown).
Table 1
Clusters of patients infected with the same B. multivorans strain
Treatment center Number of patientsa Clustersb
Two Three Four Five Six
A 41 1 2 2 ^ ^
B 38 6 1 ^ ^ ^
C 22 1 ^ ^ ^ ^
D 18 1 ^ ^ ^ ^
E 17 2 1 ^ ^ 1
F 15 ^ ^ ^ ^ ^
G 15 1 ^ ^ ^ ^
H 13 ^ ^ ^ ^ ^
I 13 ^ ^ ^ ^ ^
J 11 2 ^ ^ ^ ^
K 11 ^ ^ ^ ^ ^
L 11 1 ^ ^ ^ ^
M 9 ^ ^ ^ ^ ^
N 8 ^ ^ ^ 1 ^
O 8 1 ^ ^ ^ ^
P 7 ^ ^ ^ ^ ^
Q 7 ^ ^ 1 ^ ^
R 7 ^ ^ ^ ^ ^
S 7 ^ ^ ^ ^ ^
T 6 1 ^ ^ ^ ^
U 6 ^ ^ ^ ^ ^
V 6 ^ ^ ^ ^ ^
W 6 ^ ^ ^ ^ ^
X 6 1 ^ ^ ^ ^
Y 6 ^ ^ ^ ^ ^
Z 6 1 ^ ^ ^ ^
aOne isolate from each patient was analyzed.
bNumber of clusters of two, three, four, ¢ve or six patients infected
with a common strain.
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3.2. B. cepacia clusters
Two centers were identi¢ed that each cared for at least
six patients infected with B. cepacia. Among the eight
patients in the ¢rst center were three patients infected
with a common strain. The second center also cared for
eight B. cepacia-infected patients. Seven of these eight pa-
tients harbored the same strain. Isolates from these seven
patients clustered with a similarity coe⁄cient of 88% (Fig.
1B). PFGE analysis showed that all seven isolates had
Fig. 1. Dendrogram derived from the UPGMA linkage of Pearson’s product moment coe⁄cients between BOX-PCR patterns. A: B. multivorans isolates
from center E showing strain OHBM, and center N showing strain TUL2. Isolates AU4608 and AU3248, from centers E and N, respectively, are di¡er-
ent strain types included for comparison. B: B. cepacia (genomovar I) isolates from eight patients attending the same treatment center ; seven of eight
are strain DTN1. C: B. dolosa isolates. Isolates with AU pre¢x clustering as strain SLC6 are from patients attending the same treatment center ; 20 ad-
ditional patients from this center were infected with this strain as well (not shown). Isolate PC520 was involved in an episode of person-to-person trans-
mission of ‘Pseudomonas cepacia’ reported in 1990 [24]. The remaining six isolates shown are from CF patients receiving care in other US treatment
centers (isolates AU5526, AU3960 and AU2846) or in three European countries (isolates HI2914, HI3239 and HI3043).
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identical banding patterns (data not shown). This strain
has been designated DTN1.
3.3. B. dolosa cluster
Only one treatment center cared for six or more patients
infected with B. dolosa. In this single center, 28 patients
infected with B. dolosa received care. Genotyping analysis
revealed that all 28 patients were infected with the same
strain. These 28 isolates clustered by BOX-PCR with a
similarity coe⁄cient of 91% (Fig. 1C). PFGE analysis
demonstrated that all 28 isolates had banding pro¢les
that did not di¡er by more than two bands. This strain
has been designated SLC6.
4. Discussion
Previous studies employing bacterial genotyping analy-
ses have identi¢ed B. cepacia complex strains that are
shared by multiple CF patients, implying acquisition
from a common source or inter-patient transmission.
Few such strains, however, have been described in detail.
Strain ET12 is common among CF patients in eastern
Canada and the UK [14,15], while strain PHDC and the
‘Midwest clone’ each infect multiple patients in the USA
[16,17]. These three strains, as well as several other ‘epi-
demic’ strains reported by Mahenthiralingam et al. [18],
reside in B. cenocepacia.
Evidence of shared strains from among the remaining
B. cepacia complex species is limited. B. multivorans is the
only other species reported to date as being implicated
in possible inter-patient transmission. Segonds et al. [19]
reported two strains of B. multivorans that were common
among French CF patients. The strain involved in an out-
break among pediatric CF patients in Glasgow described
by Whiteford et al. [20] as well as the strain common
among four adult CF patients in Cardi¡ reported by Mil-
lar-Jones et al. [21] were also subsequently found to be
B. multivorans [22,23]. In contrast, Mahenthiralingam et
al. [18] found very little evidence of inter-patient spread
of B. multivorans in Vancouver, BC, during a 17-year pe-
riod.
Among the 360 patients assessed in the study reported
here, most (319 patients) were infected with B. multivorans,
which accounts for approximately 38% of B. cepacia com-
plex-infected CF patients in the USA [7]. Although shared
B. multivorans strains were found in more than half (14 of
26) of the treatment centers investigated, most were found
only in pairs of non-sibling patients. A few clusters of
three and four patients each were identi¢ed, but among
this large sampling of patients and treatment centers we
found only a single group of ¢ve and another group of six
patients infected with a common strain. These results in-
dicate that despite its relatively common occurrence in CF,
B. multivorans is only infrequently shared among patients.
These data suggest that most infections result from acqui-
sition of distinct strains from independent sites.
Infections with B. cepacia (genomovar I) and B. dolosa
(genomovar VI) occur much less frequently in CF [7].
Only two centers were identi¢ed that cared for six or
more B. cepacia-infected patients, but in both we found
shared strains. More interesting was the single center that
cares for multiple patients infected with B. dolosa. Al-
though this species accounts for only approximately 3%
of B. cepacia complex infection in US CF patients (unpub-
lished data), it is responsible for 35% of infection in this
center. Because genotyping analysis using both BOX-PCR
and PFGE demonstrated that all B. dolosa-infected pa-
tients in this center carried the same strain (designated
SLC6), we further analyzed several epidemiologically un-
related B. dolosa isolates to better assess the genetic diver-
sity within this species. Strains obtained from B. dolosa-
infected CF patients receiving care in other US centers
or in other countries were clearly distinct from strain
SLC6 (Fig. 1C). Of great interest is our ¢nding that
strain SLC6 is now identi¢ed as the strain (represented
by PC520 in Fig. 1C) implicated in the ¢rst reports of
inter-patient spread and inapparent (i.e. sputum culture-
negative) infection by ‘B. cepacia’ in CF in the early 1990s
[24,25].
Our results may actually underestimate the degree to
which non-B. cenocepacia strains are shared by CF pa-
tients. Because we were most interested in identifying rel-
atively large clusters of shared strains, we chose to inves-
tigate only centers with at least six patients infected with
non-B. cenocepacia species. Had we analyzed isolates from
all patients whom we have con¢rmed as infected with
B. cepacia complex, we expect that we would have identi-
¢ed more small (i.e. two or three patient) clusters with the
same strain.
Further, we deliberately set a relatively high similarity
coe⁄cient cuto¡ value with which to de¢ne strain types in
this study. The appropriate cuto¡ value to be applied in
an epidemiologic study is di⁄cult to determine a priori, as
it is a function of the genetic diversity within the species
investigated, the discriminatory power of the typing meth-
od used and the epidemiologic question being addressed
[12]. In a previous study, a BOX-PCR similarity cuto¡
of 70% was deemed most appropriate when assessing
the global population structure of B. cenocepacia [12]. In
the present study, in which only intra-center comparisons
were made of strains recovered during relatively short pe-
riods of time, a higher cuto¡ was necessary to provide
a more rigorous de¢nition of clonality. Had we used a
less conservative (i.e. lower) cuto¡ value to de¢ne a strain,
we most certainly would have identi¢ed more clusters,
particularly amongst the B. multivorans-infected patients.
Such a lower cuto¡ value may be appropriate in studies
assessing larger-scale inter-center comparisons, which were
beyond the scope of the present study. Further work will
be required to better establish the most appropriate cut-
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o¡(s) to be used, again depending on the speci¢c study
objectives.
We found that isolates belonging to the major strain
types de¢ned in this study (for which strain designations
were provided) all clustered with approximately 90% sim-
ilarity. We are con¢dent that these isolates do indeed rep-
resent a single strain. In previous work we found that
B. cepacia complex isolates serially recovered from the
same patient over periods of up to 4 years also typically
cluster by BOX-PCR at approximately 90%. Furthermore,
PFGE analysis using published interpretive criteria [13]
con¢rmed the clonality of the isolates we placed in the
same strain type by BOX-PCR analysis.
The epidemiologic basis of our ¢ndings and their impli-
cations for infection control and clinical outcome are not
entirely clear. Previous epidemiologic studies, supported
by bacterial genotyping analyses, have provided compel-
ling evidence for person-to-person spread of some B. ce-
pacia complex strains. In the present study, however, we
did not have access to information regarding speci¢c con-
tact among patients, either within treatment centers or in
social settings. Further, on the basis of our data we cannot
rule out acquisition from a common source or infection by
a strain that dominates in the local environment. Surveys
of environmental cultures from multiple treatment centers
searching for common strain types were beyond the scope
of the current study. If inter-patient transmission is pri-
marily responsible for our ¢ndings, the factors that ac-
count for this apparent enhanced capacity for spread re-
main to be elucidated. B. cenocepacia strain ET12 is
characterized by distinctive ‘cable pili’ [26], but this phe-
notype appears to be restricted to this strain only. ET12
and several, but not all, other ‘epidemic’ B. cenocepacia
strains also contain the ‘B. cepacia epidemic strain marker’
(BCESM) [18]. In our study, neither cable pili nor the
BCESM were found in any of the major clones identi¢ed
(data not shown).
Although strains shared by multiple CF patients are
often assumed to be more virulent in this population, large
systematic clinical outcomes studies to support this con-
tention are lacking. Similarly, a detailed assessment of
patient clinical parameters relative to infecting strain was
not possible within the context of our investigation. Thus,
we must be careful to point out that we are not able to
draw conclusions regarding the relative virulence of the
common strain types identi¢ed.
In summary, we found strains of B. cepacia, B. multi-
vorans and B. dolosa that are shared by multiple CF pa-
tients. Although the basis for these observations remains
to be elucidated, the data suggest that B. cepacia complex
other than B. cenocepacia are able to spread among CF
patients. The microbiologic factors that account for this
are the subject of ongoing investigation. Our data also
indicate that the possibility of inter-patient transmission
of non-B. cenocepacia strains should be taken into account
in designing infection control measures in CF.
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